down arrow

R&G PharmaStudies Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005K44
CNY
55.43
4.18 (8.16%)

Dec 16

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
R&G PharmaStudies Co., Ltd.
Why is R&G PharmaStudies Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 6.12% and Operating profit at 0.32% over the last 5 years
2
Flat results in Mar 25
  • INTEREST(HY) At CNY 1.68 MM has Grown at 148.8%
  • INTEREST COVERAGE RATIO(Q) Lowest at 2,582.99
  • DEBT-EQUITY RATIO (HY) Highest at -89.4 %
3
With ROE of 7.16%, it has a attractive valuation with a 1.61 Price to Book Value
  • Over the past year, while the stock has generated a return of -4.35%, its profits have risen by 6.3%
  • At the current price, the company has a high dividend yield of 0.3
4
Underperformed the market in the last 1 year
  • Even though the market (China Shanghai Composite) has generated returns of 15.18% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -4.35% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to R&G PharmaStudies Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is R&G PharmaStudies Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
R&G PharmaStudies Co., Ltd.
-100.0%
1.05
56.77%
China Shanghai Composite
14.03%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
6.12%
EBIT Growth (5y)
0.32%
EBIT to Interest (avg)
71.87
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.40
Tax Ratio
9.65%
Dividend Payout Ratio
10.88%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2,584.81%
ROE (avg)
2,376.51%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
1.61
EV to EBIT
10.67
EV to EBITDA
8.21
EV to Capital Employed
7.46
EV to Sales
1.78
PEG Ratio
NA
Dividend Yield
0.30%
ROCE (Latest)
69.92%
ROE (Latest)
7.16%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
Icon
NO KEY POSITIVE TRIGGERS
-15What is not working for the Company
INTEREST(HY)

At CNY 1.68 MM has Grown at 148.8%

INTEREST COVERAGE RATIO(Q)

Lowest at 2,582.99

DEBT-EQUITY RATIO (HY)

Highest at -89.4 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.63%

NET SALES(Q)

Lowest at CNY 172.07 MM

OPERATING PROFIT(Q)

Lowest at CNY 21.52 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 12.51 %

Here's what is not working for R&G PharmaStudies Co., Ltd.
Interest
At CNY 1.68 MM has Grown at 148.8%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest Coverage Ratio
Lowest at 2,582.99
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Sales
Lowest at CNY 172.07 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit
Lowest at CNY 21.52 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin
Lowest at 12.51 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Debt-Equity Ratio
Highest at -89.4 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 2.63%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."